Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Nordisk Dismayed By “Complete Response” Letter For Insulin Degludec

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA is requesting data from a dedicated cardiovascular outcomes trial before approving the ultra-long-acting insulins Tresiba and Ryzodeg. News of the regulatory setback caused a 13% drop in the company’s stock price on Feb. 11.

You may also be interested in...



Novo Nordisk Flaunts Tresiba To Outsmart Sanofi’s Lantus In India

After widening the gap with competitors in the insulin market by a huge margin, Novo Nordisk is preparing to launch Tresiba and take a shot at the long-acting basal insulin market, a stronghold preserved by Sanofi globally. Will Tresiba firmly establish Novo Nordisk as the unquestionable insulin leader?

Once-Weekly Insulin Added To Novo Nordisk’s Clinical Pipeline

Novo Nordisk is evaluating new long-acting and quick-acting insulins in clinical trials as competitive pressure looks set to intensify in 2013 for its market-leading GLP-1 agonist, Victoza.

Novo’s Insulin Degludec Faces Advisory Cmte. Scrutiny On Hypoglycemic Benefit, CV Safety

In briefing documents for the Nov. 8 panel review, FDA suggests the clinical trial data do not support Novo Nordisk’s assertion of a hypoglycemia advantage with its new long-acting insulin. Agency also raises concerns about a meta-analysis suggesting an increased cardiovascular risk.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel